Miracle cures or modern quackery? Stem cell clinics multiply, with … – Washington Post
Washington Post |
Miracle cures or modern quackery? Stem cell clinics multiply, with …
Washington Post Doris Tyler lay on the examining table as the doctor stuck a long, thin tube into her belly. The doctor pulled back a plunger, and the syringe quickly filled with yellow blobs tinged with pink. “Look at that beautiful fat coming out. Liquid gold!” one … Which Way on Stem Cells?City Journal Government to demarcate ‘stem cell therapy’ from ‘stem cell drug’Economic Times As stem cell clinics multiply, so do legal complaintsSFGate |
City Journal |
Which Way on Stem Cells?
City Journal Last month, FDA commissioner Scott Gottlieb and Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, coauthored a special report in the New England Journal of Medicine entitled “Balancing Safety and Innovation for Cell-Based … |
Economic Times |
Government to demarcate ‘stem cell therapy’ from ‘stem cell drug’
Economic Times NEW DELHI: To ensure unhindered access of ‘stem cell therapy’ for treatment by physicians, the Union Health Ministry has proposed to statutory distinguish it from ‘stem cell drugs,’ making the latter alone liable to the usual screening and trial runs … Golden Bear Jack Nicklaus Undergoes Experimental Stem Cell …Tech Times Stem cell caution to govt – Telegraph IndiaThe Telegraph India Jack Nicklaus Says He Had Experimental Stem Cell Treatment For His Back PainThe Inquisitr Checkbiotech.org (press release) –India Today all 17 news articles » |
Herald Sun |
Mini-organs from stem cells used to uncover kidney disease genes
Herald Sun The Murdoch Children’s Research Institute’s Dr Sara Howden created stem cells from a skin biopsy and used the gene-editing technology, CRISPR, to correct the mutation in her cells. Two mini-kidneys were grown in a dish, one with her disease and the … |
Bloomberg |
Berkeley Fights Harvard, MIT Over Profits From Gene-Editing Tech
Bloomberg “I’m a company and I want to practice CRISPR, who do I license, who do I pay?” said Kevin Noonan, a biotechnology lawyer with McDonnel Boehnen Hulbert & Berghoff in Chicago. Universities and start-up companies primarily in the U.S. and China are … |